ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

por Lemech, Charlotte Rose, Kichenadasse, Ganessan, Marschner, Jens-Peter, Alevizopoulos, Konstantinos, Otterlei, Marit, Millward, Michael
Publicado 2022